Personalised blood test can detect persistent lung cancer

cjb250 — Thu, 17 Mar 2022 13:00:14 +0000

Scientists at the Cancer Research UK Cambridge Institute used a personalised blood test for patients, which is a type of liquid biopsy that can pick up tiny fragments of DNA that are released into the blood as tumours grow. This DNA, called circulating tumour DNA (ctDNA), can reveal the state of the tumour, its location and potentially its weaknesses, which could be used to select the best treatments.

̽��ֱ��results from the Lung Cancer Circulating Tumour DNA (LUCID-DNA) study, funded by Cancer Research UK, have been published today in the Annals of Oncology.

Many patients who are treated for early-stage non-small cell lung cancer can be cured with either surgery, radiotherapy or sometimes (chemo)radiotherapy.

After treatment, lung cancer patients are carefully followed up with tests including CT scans to find out if the treatment has removed the tumour, but scans won’t pick up tiny quantities of cancer cells known as minimal residual disease (MRD) which could still regrow into further tumours.

By finding signs that lung cancer cells might still be present and active after treatment, using methods such a liquid biopsy, doctors might be able make better choices about treating patients, aiming to improve the chances of survival for patients who are at higher risk while reducing side effects for patients who are at a lower risk group.

̽��ֱ��LUCID-DNA study aimed to find out if circulating DNA can be detected in early stage lung cancers. It used a liquid biopsy, called RaDaR™, which analyses up to 48 different mutations that are unique to each patient’s tumour. RaDaR™ was developed by Inivata, a biotech company co-founded by Dr Rosenfeld, and is based on technologies developed initially by his lab at the Cancer Research UK Cambridge Institute.

Dr Nitzan Rosenfeld, group leader at the Cancer Research UK Cambridge Institute, Chief Scientific Officer of Inivata and co-lead author of the study, said: “If cancer cells remain in the body after treatment a tumour can regrow. If that happens, it is a big setback for patients and the doctors treating them.

“Liquid biopsy can be used to detect tiny amounts of residual cancer after treatment, flagging those patients who have signs that their tumour may not have been eradicated completely with treatment. We’re hoping that this technology could help doctors decide when additional rounds of treatment are needed, and could save lives.”

To find out if liquid biopsy could find lung cancer patients with MRD, the LUCID-DNA study team enrolled 88 patients who were treated at Royal Papworth Hospital and Addenbrooke’s Hospital for early stage non-small cell lung cancer. This type of cancer accounts for over 85% of all lung cancer cases.

̽��ֱ��research team extracted DNA from tumour samples provided by the patients and sequenced the DNA to find combinations of mutations unique to each patient’s lung cancer. Using this genetic “fingerprint”, Inivata created a blood test which was personalised to the patient’s tumour.

̽��ֱ��liquid biopsies were then used to detect tumour DNA in blood samples collected before treatment, and for up to 9 months after treatment. ̽��ֱ��researchers found that patients who had tumour DNA present between two weeks and four months after treatment were much more likely to have their lung cancer come back or to die from it.

Professor Robert Rintoul, Professor of Thoracic Oncology at the ̽��ֱ�� of Cambridge, Honorary Respiratory Physician at Royal Papworth Hospital and co-lead author of the study, said: “We need to study these liquid biopsies further to find the best ways to deploy them, but these results clearly show that they can potentially be an effective tool to help decide which patients need further treatment.

“Being able to offer patients personalised monitoring and treatment will ultimately save more lives and help us to beat cancer sooner.”

Lung cancer is the third most common type of cancer in the UK. Every year, around 48,500 people are diagnosed with lung cancer and every year around 35,100 people die from the disease in the UK.

Aart Alders participated in the LUCID-DNA observational clinical study at Royal Papworth Hospital following his lung cancer surgery.

“I was first diagnosed with an early-stage lung cancer about five years ago and underwent a surgical operation to remove it,” he said. “Although some people need further treatment with chemotherapy, I have been very fortunate and my original lung cancer has not returned.

“I was very pleased to be able to help with the LUCID-DNA research study. By trying to develop a blood test to help doctors predict whether a lung cancer might come back or not, we will increase the chance of curing more people.”

Michelle Mitchell, Chief Executive of Cancer Research UK, said: “Lung cancer is one of the biggest killers in the UK. ̽��ֱ��earlier it is caught, the more likely it is to be treated successfully.

“Detecting signs of cancer before or after treatment without the need for invasive surgery has huge potential for both patients and doctors.

“I look forward to seeing more research that will develop liquid biopsy further, which will and ultimately make it much easier for doctors to offer treatment that best matches the patient’s needs, increasing their chance of survival.”

Adapted from a press release by Cancer Research UK

Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, according to researchers at the ̽��ֱ�� of Cambridge.

Liquid biopsy can be used to detect tiny amounts of residual cancer after treatment, flagging those patients who have signs that their tumour may not have been eradicated completely with treatment

Nitzan Rosenfeld

Belova59

Blood test

̽��ֱ��text in this work is licensed under a Creative Commons Attribution 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Licence type:

Public Domain

Recruitment underway as Cambridgeshire NHS trusts join COVID-19 vaccine trial

Anonymous — Thu, 11 Jun 2020 07:49:43 +0000

̽��ֱ��COV002 trial, developed by the ̽��ֱ�� of Oxford, aims to assess how well people across a broad range of ages could be protected from COVID-19 using a new vaccine called ChAdOx1 nCoV-19. It will also provide valuable information on safety of the vaccine and its ability to generate good immune responses against the virus.

Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), Cambridge ̽��ֱ�� Hospitals NHS Foundation Trust and Royal Papworth Hospital NHS Foundation Trust are recruiting healthy staff aged between 18-55 years old who have not been infected with coronavirus but have regular face-to-face contact with COVID-19 patients, to take part in the trial.

Eligible participants will be randomised to receive one dose of either the trial vaccine (ChAdOx1 nCoV-19) or a licensed meningitis vaccine (MenACWY) that will be used as a ‘control’ for comparison. Following vaccination, participants will be followed up over 12 months.

Dr Estée Török from the Department of Medicine at the ̽��ֱ�� of Cambridge and Principal Investigator at Cambridge ̽��ֱ�� Hospitals NHS Foundation Trust, said: “Developing an effective vaccine is key to controlling the COVID-19 pandemic. We are delighted to be working with CPFT and Royal Papworth on this UK national priority vaccine trial. We are looking for healthy volunteers at high risk of COVID-19 infection at CUH to participate in this study and are most grateful to them for doing so.”

Dr Ben Underwood, Deputy Medical Director and Principal Investigator (study lead) at CPFT said: “We are grateful to all our staff for their brilliant response to the coronavirus pandemic. Our research teams are playing a vital role in international efforts to secure a vaccine, which we hope will protect those most at risk, save more lives and minimise the disruption caused by the virus. Thank you to all volunteers who take part and make clinical trials possible.”

Dr Robert Rintoul, Director, Papworth Trials Unit Collaboration, and Reader in Thoracic Oncology at the Department of Oncology, ̽��ֱ�� of Cambridge, said: “We at Royal Papworth Hospital are proud to be supporting research into possible vaccines and treatments for COVID-19. I would like to thank our staff members who have chosen to participate in this important public health project.”

Adapted from a press release by Cambridge ̽��ֱ�� Health Partners.

Recruitment has begun at three leading Cambridgeshire NHS Trusts for volunteers to take part in the nationwide COVID-19 vaccine trial.

Developing an effective vaccine is key to controlling the COVID-19 pandemic

Estee Torok

geralt

Coronavirus

Yes

Licence type:

Public Domain

̽��ֱ�� of Cambridge - Robert Rintoul

Personalised blood test can detect persistent lung cancer

Recruitment underway as Cambridgeshire NHS trusts join COVID-19 vaccine trial